帕金森病和正常衰老中的胆固醇中心-状网络
Nicolaas I Bohnen1,2,3,4, Sygrid van der Zee5,6, Roger Albin2,3,4,7
1Department of Radiology, University of Michigan, Ann Arbor, MI 48105, USA.
Aging
|October 29, 2023
概括
中心状网络中的胆固醇缺陷与帕金森病 (PD) 中的认知和运动问题有关. 这些在正常衰老中也可见的变化表明,联合治疗策略可能有利于神经退行性疾病.
科学领域:
- 神经科学是一个神经科学.
- 神经退行性疾病 神经退行性疾病
- 认知神经学 认知神经学
背景情况:
- 胆固醇系统功能障碍与帕金森病 (PD) 的认知和运动障碍有关.
- 对于认知和运动控制至关重要的中枢神经神经网络,在PD中显示了胆固醇结合的减少.
- 正常的衰老还涉及胆固醇神经末端的脆弱性,特别是在中枢状网络.
研究的目的:
- 探索中枢神经网络中胆固醇结合与PD的认知/运动缺陷之间的相关性.
- 研究前部中皮质在运动控制和体认知整合中的作用.
- 了解与PD相关的和与年龄相关的胆固醇系统变化之间的重叠.
主要方法:
- 关于大脑网络和胆固醇功能MRI神经成像研究的综述.
- 分析中枢状网络完整性与PD症状严重程度之间的关系.
- 检查与效应器和效应器间控制相关的新型初级运动皮质组织.
主要成果:
- 中心状网络中胆固醇结合的减少与PD认知障碍严重程度有很强的相关性.
- 这种网络还与帕金森症的运动障碍相关,如姿势不稳定和步行困难.
- 有证据表明,运动皮层中的交互效应区域与单眼和眼区域联系在一起,形成一个体质认知行动网络.
结论:
- 中心状网络中的胆固醇缺陷是PD病理生理学的核心.
- 与年龄相关的胆固醇脆弱性有助于神经退行,这表明共享的病因因素.
- 针对疾病特异性和与衰老相关的机制的治疗策略可能对具有胆固醇系统退化的神经退行性疾病有益.
相关概念视频
01:24Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
01:37Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
01:15Parkinson's Disease: Overview
567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567
01:26Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
01:23Cholinergic Neurons: Neurotransmission
3.0K
Cholinergic neurotransmission involves the synthesis and the release of acetylcholine (ACh) in order to transmit nerve impulses across the synapse. The process begins with the synthesis of acetyl CoA, a precursor for ACh, from ATP, acetate, and coenzyme A in the mitochondria. Choline, another vital precursor, is transported inside the neuron through choline transporters, including high-affinity choline transporter CHT1, low-affinity choline transporter CTL1, and lower-affinity choline...
3.0K
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200